Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Operable breast cancer.

M Cianfrocca1, L J Goldstein

  • 1Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

An automated tube-type blood viscometer: validation studies.

Biorheology·2005
Same author

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2004
Same author

Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.

Bone marrow transplantation·2003
Same author

Response time of the Opti-Q continuous cardiac output pulmonary artery catheter in the urgent mode to a step change in cardiac output.

Journal of clinical monitoring and computing·2003
Same author

Stroke in surgery of the thoracic aorta: incidence, impact, etiology, and prevention.

The Journal of thoracic and cardiovascular surgery·2001
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Adjuvant therapy significantly improves survival for breast cancer patients. Standard treatments include tamoxifen for hormone-positive cases and chemotherapy for node-positive or high-risk patients.

Area of Science:

  • Oncology
  • Medical Malignancies

Background:

  • Breast cancer is the most prevalent cancer in American women.
  • Widespread screening leads to early detection and curative treatment for most patients.
  • Adjuvant therapy is crucial for enhancing disease-free and overall survival in breast cancer.

Purpose of the Study:

  • To outline the standard adjuvant systemic therapy options for breast cancer.
  • To emphasize the importance of adjuvant therapy in improving patient outcomes.

Main Methods:

  • Review of established clinical practices for adjuvant breast cancer treatment.
  • Identification of standard systemic therapy options based on hormone receptor status and nodal involvement.

Main Results:

Related Experiment Videos

  • Tamoxifen is a key treatment for hormone receptor-positive breast cancer.
  • Systemic polychemotherapy is utilized for node-positive and high-risk node-negative patients.
  • Adjuvant systemic therapy is a standard component of care for specific breast cancer patient groups.

    • Conclusions:

    • Adjuvant systemic therapy is a cornerstone in managing operable breast cancer.
    • Appropriate adjuvant treatment significantly improves survival rates.
    • Standard practice dictates adjuvant therapy for node-positive and high-risk node-negative breast cancer.